CDEK
← All drugs Report issue

rpl554

Small moleculeexperimental

Clinical trial activity

9 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
8
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2014 (NCT02307162)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimidino(6,1-a)isoquinolin-4-one
  • rpl554
  • rpl554
  • rpl554
  • rpl 554
  • rpl-554

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06460493Phase 3Jun 11, 2024Verona Pharma plc
NCT04027439Phase 2Dec 10, 2018IQVIA, Verona Pharma plc, Vitalink Research
NCT03673670Phase 2Jul 16, 2018University of Manchester, Verona Pharma plc
NCT03443414Phase 2Jun 1, 2017Verona Pharma plc
NCT02919995Phase 2Feb 1, 2017Cystic Fibrosis Trust, Papworth Hospital NHS Foundation Trust, Verona Pharma plc
NCT03028142Phase 2Jan 1, 2017Verona Pharma plc
NCT02542254Phase 2Oct 1, 2015University of Manchester, Verona Pharma plc
NCT02427165Phase 2Apr 1, 2015Celerion, Lund University, Verona Pharma plc
NCT02307162Phase 1Dec 1, 2014University of Manchester, Verona Pharma plc
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Verona Pharma plcFor profit9932014
University of ManchesterAcademic/Hospital3022014
CelerionFor profit1012015
Cystic Fibrosis TrustAcademic/Hospital1012017
IQVIAFor profit1012018
Lund UniversityAcademic/Hospital1012015
Papworth Hospital NHS Foundation TrustAcademic/Hospital1012017
Vitalink ResearchFor profit1012018
8 organizations
Page 1 / 1